Literature DB >> 19959934

Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?

Stanley Zucker1, Jian Cao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19959934      PMCID： PMC2829367          DOI： 10.4161/cbt.8.24.10353

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


× No keyword cloud information.
  20 in total

Review 1.  MT1-MMP: a potent modifier of pericellular microenvironment.

Authors:  Yoshifumi Itoh; Motoharu Seiki
Journal:  J Cell Physiol       Date:  2006-01       Impact factor: 6.384

Review 2.  Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.

Authors:  Christopher M Overall; Oded Kleifeld
Journal:  Nat Rev Cancer       Date:  2006-03       Impact factor: 60.716

3.  Rac activation and inactivation control plasticity of tumor cell movement.

Authors:  Victoria Sanz-Moreno; Gilles Gadea; Jessica Ahn; Hugh Paterson; Pierfrancesco Marra; Sophie Pinner; Erik Sahai; Christopher J Marshall
Journal:  Cell       Date:  2008-10-31       Impact factor: 41.582

4.  Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.

Authors:  Nicholas Robert; Brian Leyland-Jones; Lina Asmar; Robert Belt; Des Ilegbodu; David Loesch; Robert Raju; Elizabeth Valentine; Robert Sayre; Melody Cobleigh; Kathy Albain; Cecelia McCullough; Lea Fuchs; Dennis Slamon
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

5.  Tumor targeting with a selective gelatinase inhibitor.

Authors:  E Koivunen; W Arap; H Valtanen; A Rainisalo; O P Medina; P Heikkilä; C Kantor; C G Gahmberg; T Salo; Y T Konttinen; T Sorsa; E Ruoslahti; R Pasqualini
Journal:  Nat Biotechnol       Date:  1999-08       Impact factor: 54.908

6.  Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196.

Authors:  Joseph A Sparano; Patricia Bernardo; Patricia Stephenson; William J Gradishar; James N Ingle; Stanley Zucker; Nancy E Davidson
Journal:  J Clin Oncol       Date:  2004-12-01       Impact factor: 44.544

Review 7.  A bioinorganic perspective on matrix metalloproteinase inhibition.

Authors:  David T Puerta; Seth M Cohen
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

8.  Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta1-induced pericellular collagenolysis.

Authors:  Hidayatullah G Munshi; Yi I Wu; Subhendu Mukhopadhyay; Adam J Ottaviano; Antonella Sassano; Jennifer E Koblinski; Leonidas C Platanias; M Sharon Stack
Journal:  J Biol Chem       Date:  2004-07-09       Impact factor: 5.157

9.  Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis.

Authors:  Laetitia Devy; Lili Huang; Laurent Naa; Niranjan Yanamandra; Henk Pieters; Nicolas Frans; Edward Chang; Qingfeng Tao; Marc Vanhove; Annabelle Lejeune; Reinoud van Gool; Daniel J Sexton; Guannan Kuang; Douglas Rank; Shannon Hogan; Csaba Pazmany; Yu Lu Ma; Sonia Schoonbroodt; Andrew E Nixon; Robert C Ladner; Rene Hoet; Paula Henderikx; Chris Tenhoor; Shafaat A Rabbani; Maria Luisa Valentino; Clive R Wood; Daniel T Dransfield
Journal:  Cancer Res       Date:  2009-02-10       Impact factor: 12.701

10.  Diversity of human pancreatic cancer cell proteinases: role of cell membrane metalloproteinases in collagenolysis and cytolysis.

Authors:  S Zucker; R M Lysik; J Wieman; D P Wilkie; B Lane
Journal:  Cancer Res       Date:  1985-12       Impact factor: 12.701
View more
  39 in total

1.  Constitutive K-RasG12D activation of ERK2 specifically regulates 3D invasion of human pancreatic cancer cells via MMP-1.

Authors:  Gregory P Botta; Mauricio J Reginato; Maximilian Reichert; Anil K Rustgi; Peter I Lelkes
Journal:  Mol Cancer Res       Date:  2011-12-08       Impact factor: 5.852

2.  Differentiation of prostate cancer cells using flexible fluorescent polymers.

Authors:  Michael D Scott; Rinku Dutta; Manas K Haldar; Bin Guo; Daniel L Friesner; Sanku Mallik
Journal:  Anal Chem       Date:  2011-12-14       Impact factor: 6.986

Review 3.  Cathepsin L targeting in cancer treatment.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Pharmacol Ther       Date:  2015-08-20       Impact factor: 12.310

4.  Generation of Highly Selective MMP Antibody Inhibitors.

Authors:  Dong Hyun Nam; Xin Ge
Journal:  Methods Mol Biol       Date:  2018

Review 5.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

6.  Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies.

Authors:  Sabrina Amar; Gregg B Fields
Journal:  Expert Rev Proteomics       Date:  2015-07-15       Impact factor: 3.940

7.  Generation of inhibitory monoclonal antibodies targeting matrix metalloproteinase-14 by motif grafting and CDR optimization.

Authors:  Dong Hyun Nam; Kuili Fang; Carlos Rodriguez; Tyler Lopez; Xin Ge
Journal:  Protein Eng Des Sel       Date:  2016-12-15       Impact factor: 1.650

Review 8.  The interplay between the proteolytic, invasive, and adhesive domains of invadopodia and their roles in cancer invasion.

Authors:  Or-Yam Revach; Benjamin Geiger
Journal:  Cell Adh Migr       Date:  2014       Impact factor: 3.405

Review 9.  The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.

Authors:  T F Sumter; L Xian; T Huso; M Koo; Y-T Chang; T N Almasri; L Chia; C Inglis; D Reid; L M S Resar
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

10.  Original Research: The expression of MMP2 and MMP9 in the hippocampus and cerebral cortex of newborn mice under maternal lead exposure.

Authors:  Ning Li; Xing Li; Li Li; Pingan Zhang; Mingwu Qiao; Qiuyan Zhao; Lianjun Song; Zengli Yu
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.